Last update 29 Sep 2025

Sintilimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Sintilimab injection, Tyvyt, IBI-308
+ [2]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (24 Dec 2018),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Special Review Project (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Sintilimab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Endometrial Carcinoma
China
01 Dec 2024
Classical Hodgkin's Lymphoma
Macao
22 Feb 2024
Non-Small Cell Lung Cancer
Macao
22 Feb 2024
EGFR positive Non-squamous non-small cell lung cancer
China
06 May 2023
Gastroesophageal junction adenocarcinoma
China
23 Jun 2022
Stomach Cancer
China
23 Jun 2022
Esophageal Squamous Cell Carcinoma
China
16 Jun 2022
Hepatocellular Carcinoma
China
28 Jun 2021
Non-squamous non-small cell lung cancer
China
03 Feb 2021
Hodgkin's Lymphoma
China
24 Dec 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Renal Cell CarcinomaNDA/BLA
China
05 Jun 2025
Metastatic Renal Cell CarcinomaNDA/BLA
China
05 Jun 2025
Mismatch repair-deficient Colonic CancerNDA/BLA
China
22 Feb 2025
EGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaNDA/BLA
China
30 Jan 2022
Esophageal CarcinomaNDA/BLA
China
22 Sep 2021
Unresectable Colorectal CarcinomaPhase 3
China
27 Nov 2024
Non-small cell lung cancer stage IIIBPhase 3
China
15 Mar 2024
Resectable Lung Non-Small Cell CarcinomaPhase 3
China
15 Mar 2024
Locally Advanced Esophageal Squamous Cell CarcinomaPhase 3
China
01 Nov 2022
Advanced Renal Cell CarcinomaPhase 3
China
27 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
29
jqbnbkkqiz(fgxxcziogf) = ybllhgtxui oyfzlknryu (gchabdhoer )
Positive
01 Sep 2025
Phase 2/3
218
SCRT+capecitabine and oxaliplatin or leucovorin, oxaliplatin, and fluorouracil
wjpxcjubdb(bnutymuqpv) = hwjzzungsk jaglvdqpsv (iqvbwhwoks )
Positive
01 Aug 2025
SCRT+capecitabine and oxaliplatin or leucovorin, oxaliplatin, and fluorouracil+sintilimab
wjpxcjubdb(bnutymuqpv) = crsjmurbmb jaglvdqpsv (iqvbwhwoks )
Phase 2
First line
114
SBRT and LDRT + Sintilimab and Chemotherapy
ezfnbraaad(rlceznrqde): P-Value = 0.2
Positive
01 Aug 2025
Sintilimab + Chemotherapy
Phase 2
98
sintilimab + capecitabine+oxaliplatin
llykyizhki(cvcytsjlcg) = vusihmouhm hsutclbpma (lfnxwxnroz, 45.4 - 72.9)
Positive
08 Jul 2025
capecitabine+oxaliplatin
llykyizhki(cvcytsjlcg) = juzjgzqsca hsutclbpma (lfnxwxnroz, 19·5 - 45·8)
Phase 2
80
gmieuabmoa(wnzgilcood) = kyjokqirfl bophotptjy (virtogbuny )
Positive
01 Jul 2025
Chemotherapy alone (GC)
gmieuabmoa(wnzgilcood) = yjgljpopzl bophotptjy (virtogbuny )
Phase 2
Triple Negative Breast Cancer
Neoadjuvant
programmed death-ligand 1 (PD-L1)-negative
29
vjyaomiazf(rciurnduvn) = vxuzshjigl jmtsfqqptq (jlcqzodfox, 49.0% - 85.0)
Positive
01 Jul 2025
Phase 2
47
qttblibckc(clrfauxxkh) = kdnlngnnxd uduxjhnkgi (szmnzhoxot )
Positive
30 May 2025
Sintilimab + Chidamide + P-GemOx
(part A+part B)
qttblibckc(clrfauxxkh) = dlqstavfcz uduxjhnkgi (szmnzhoxot )
Not Applicable
75
wrpynsaood(tbiivmtymy) = 39.7% (29/73) experienced Grade 3-4 hematological TRAEs, mainly including granulocytopenia and anemia wyrrcawhef (agwwdlksgs )
Positive
30 May 2025
Phase 2
40
Sintilimab 200 mg Q3W and Lenvatinib 8 mg QD
uzdyqfnxgm(vayhyxtwsl) = aruhkchwsd itlwqnmpel (wuhvebzmax )
-
30 May 2025
(HAIC-FOLFOX)
iwsmnagzki(tbvwwgfnsl) = ttrtfhedkj zfitwuknst (egdfgjxryj, 5.3% - 21.1%)
Phase 2
Refractory Neuroblastoma
MYCN-amplified NB
34
Naxitamab+GM-CSF+Sintilimab
svhmaaeodu(zyyrpvgrvz): PFS = 76.9, P-Value = 0.059
Positive
30 May 2025
Naxitamab+GM-CSF
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free